Martingale Asset Management’s MacroGenics MGNX Stock Holding History

Martingale Asset Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,482	Closed	-$149K	–	843
2023 Q4	$149K	Sell	15,482 -804	-5%	-$5.56K	﹤0.01%	771
2023 Q3	$75.9K	Hold	16,286	–	–	﹤0.01%	773
2023 Q2	$87.1K	Hold	16,286	–	–	﹤0.01%	790
2023 Q1	$117K	Sell	16,286 -5	-0%	-$30	﹤0.01%	803
2022 Q4	$109K	Buy	16,291 +1,617	+11%	+$8.87K	﹤0.01%	815
2022 Q3	$51K	Buy	+14,674	New	+$56.1K	﹤0.01%	816
2021 Q2	–	Sell	-7,117	Closed	-$227K	–	875
2021 Q1	$227K	Buy	+7,117	New	+$173K	﹤0.01%	796
2020 Q4	–	Sell	-9,717	Closed	-$245K	–	986
2020 Q3	$245K	Buy	9,717 +1	+0%	+$27	﹤0.01%	942
2020 Q2	$272K	Buy	+9,716	New	+$169K	﹤0.01%	953

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Martingale Asset Management's MGNX Position: Q1 2024 in Review

Martingale Asset Management sold out of MacroGenics (MGNX) in Q1 2024, closing a stake of 15,482 shares — an estimated $149K sold.

Martingale Asset Management first reported a position in MGNX in Q2 2020 and held it in 9 quarters. The position peaked at $272K in Q2 2020. 163 funds tracked by Wall St. Rank hold MGNX as of Q1 2024.

Martingale Asset Management reported no remaining MacroGenics position as of Q1 2024 after selling out during the quarter.
Martingale Asset Management sold 15,482 MacroGenics shares in Q1 2024, an estimated $149K.
Martingale Asset Management first reported a position in MacroGenics in Q2 2020 and held it in 9 quarters.
Martingale Asset Management's MacroGenics position peaked at $272K in Q2 2020.
163 funds tracked by Wall St. Rank held MacroGenics as of Q1 2024.

Based on Martingale Asset Management's 13F filing for Q1 2024, filed 14 May 2024.